Macugen Solution for Injection

S01LA03(WHO) US:℞-only RNA, ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT), 5'-ester with α,α'-[4,‍‍‍‍‍‍​​​‍​​​​​​12-dioxo-6[[[5-(phosphoonoxy)pentyl]amino]carbonyl]-3,13-dioxa-5,11-diaza-1,15-pentadecanediyl]bis[ω-methoxypoly(oxy-1,2-ethanediyl)], sodium salt 222716-86-1Y DB04895Y none 2H1PA8H1EN DTXSID40944934 Pegaptanibsodium injection (brand nameMacugen) is ananti-angiogenicmedicine for the treatment of neovascular (wet)age-related macular degeneration(AMD).It was discovered byNeXstar Pharmaceuticals(which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, nowOSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing.Outside the US pegaptanib is marketed byPfizer. Approval was granted by theU.S. Food and Drug Administration(FDA) in December 2004.